{"filing":{"accession_number":"0001683168-26-005233","cik":"0001729427","ticker":"CNSP","company_name":"CNS Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"cns_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316826005233/cns_8k.htm"},"events":[{"id":15678,"run_id":13979,"accession_number":"0001683168-26-005233","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CNS Pharmaceuticals disclosed a strategic pivot and asset acquisition strategy through an investor presentation posted on July 2, 2026. The presentation outlines a comprehensive corporate restructuring—including a new executive team, a $22.5 million financing closed in May 2026, and a disciplined asset acquisition strategy targeting oncology and neurology assets. While the filing itself is a Regulation FD disclosure of the presentation, the underlying events (strategic refocus, new leadership, capital raise, and asset search) constitute material operational and strategic changes that would affect a reasonable investor's assessment of the company's direction and value creation prospects.","company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13545,"accession_number":"0001683168-26-005233","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CNS Pharmaceuticals disclosed a strategic pivot and asset acquisition strategy through an investor presentation posted on July 2, 2026. The presentation outlines a comprehensive corporate restructuring—including a new executive team, a $22.5 million financing closed in May 2026, and a disciplined asset acquisition strategy targeting oncology and neurology assets. While the filing itself is a Regulation FD disclosure of the presentation, the underlying events (strategic refocus, new leadership, capital raise, and asset search) constitute material operational and strategic changes that would affect a reasonable investor's assessment of the company's direction and value creation prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T11:31:41.429312+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13545,"accession_number":"0001683168-26-005233","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CNS Pharmaceuticals disclosed a strategic pivot and asset acquisition strategy through an investor presentation posted on July 2, 2026. The presentation outlines a comprehensive corporate restructuring—including a new executive team, a $22.5 million financing closed in May 2026, and a disciplined asset acquisition strategy targeting oncology and neurology assets. While the filing itself is a Regulation FD disclosure of the presentation, the underlying events (strategic refocus, new leadership, capital raise, and asset search) constitute material operational and strategic changes that would affect a reasonable investor's assessment of the company's direction and value creation prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T11:31:41.429312+00:00","company_name":"CNS Pharmaceuticals, Inc.","ticker":"CNSP","filing_date":"2026-07-02"}]}